Metsera, the US-based weight problems drug developer, ended what was turning right into a bitter struggle between two of the largest pharmaceutical firms on this planet when it accepted Pfizer’s US$10 billion acquisition provide over Novo Nordisk’s upgraded bid.
Pfizer, which has been struggling since post-COVID days, is attempting to get a foothold within the rising weight-loss market. Based on Morgan Stanley, weight problems drug gross sales may develop from $15 billion final 12 months to $150 billion by 2035.
Novo and Eli Lilly have been the 2 firms which have dominated the market. Novo is the maker of Ozempic, a semaglutide that could be a GLP-1 receptor agonist. Eli Lilly is available in the market with a tirzepatide, underneath the model title Mounjaro. Novo has been attempting to get better its once-commanding place in weight problems medicine.
Pfizer made the primary transfer in September with a bid that was stated to be within the area of US$7.3 billion. Novo jumped into the image when it made an unsolicited provide of US$9 billion final week.
Beneath the phrases of the money deal, Pfizer pays $65.60 a share upfront and a contingent worth proper price as much as $20.65 a share, Metsera stated Friday.
The bidding struggle noticed Metsera’s share achieve almost 60 per cent in a single week, sending its market worth to US$8.75 billion.
On Friday, Metsera stated in an announcement: “The Metsera Board of Administrators has decided that the revised phrases symbolize one of the best transaction for shareholders, each from the attitude of worth and certainty of closing.
“As well as, in gentle of current circumstances, together with the receipt by Metsera of a name from the US Federal Commerce Fee concerning potential dangers from continuing with the proposed Novo Nordisk construction underneath US antitrust legal guidelines, the Metsera Board of Administrators has additional decided that the transaction proposed by Novo Nordisk presents unacceptably excessive authorized and regulatory dangers to Metsera and its stockholders in comparison with the proposed merger with Pfizer, together with dangers that the preliminary dividend could by no means be paid or could also be subsequently challenged or rescinded.
“Metsera stays dedicated to the merger with Pfizer, which Metsera believes will ship speedy and substantial worth to Metsera stockholders, and the events anticipate to shut promptly following the stockholder assembly on November 13.”
Metsera’s experimental weight problems medicine, MET-097i, a GLP-1 injectable, and MET-233i, which mimics the pancreatic hormone amylin, are projected to succeed in $5 billion in mixed peak gross sales, in accordance with Leerink Companions analyst David Risinger.
